Back to Search
Start Over
Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitis-Translation of Pathogenic Fundamentals Into an In Vitro Model.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Jan 11; Vol. 11, pp. 622511. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2020). - Publication Year :
- 2021
-
Abstract
- Interface dermatitis is a histopathological pattern mirroring a distinct cytotoxic immune response shared by a number of clinically diverse inflammatory skin diseases amongst which lichen planus and cutaneous lupus erythematosus are considered prototypic. Interface dermatitis is characterized by pronounced cytotoxic immune cell infiltration and necroptotic keratinocytes at the dermoepidermal junction. The initial inflammatory reaction is established by cytotoxic immune cells that express CXC chemokine receptor 3 and lesional keratinocytes that produce corresponding ligands, CXC motif ligands 9/10/11, recruiting the effector cells to the site of inflammation. During the resulting anti-epithelial attack, endogenous immune complexes and nucleic acids are released from perishing keratinocytes, which are then perceived by the innate immune system as danger signals. Keratinocytes express a distinct signature of pattern recognition receptors and binding of endogenous nucleic acid motifs to these receptors results in interferon-mediated immune responses and further enhancement of CXC chemokine receptor 3 ligand production. In this perspective article, we will discuss the role of innate nucleic acid sensing as a common mechanism in the perpetuation of clinically heterogeneous diseases featuring interface dermatitis based on own data and a review of the literature. Furthermore, we will introduce a keratinocyte-specific in vitro model of interface dermatitis as follows: Stimulation of human keratinocytes with endogenous nucleic acids alone and in combination with interferon gamma leads to pronounced production of distinct cytokines, which are essential in the pathogenesis of interface dermatitis. This experimental approach bears the capability to investigate potential therapeutics in this group of diseases with unmet medical need.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Braegelmann, Fetter, Niebel, Dietz, Bieber and Wenzel.)
- Subjects :
- Chemokines, CXC immunology
Dermatitis drug therapy
Dermatitis pathology
Humans
Lichen Planus drug therapy
Lichen Planus pathology
Lupus Erythematosus, Cutaneous drug therapy
Lupus Erythematosus, Cutaneous pathology
Nucleic Acids immunology
Adjuvants, Immunologic therapeutic use
Dermatitis immunology
Lichen Planus immunology
Lupus Erythematosus, Cutaneous immunology
Models, Immunological
Nucleic Acids therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33505404
- Full Text :
- https://doi.org/10.3389/fimmu.2020.622511